Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 5Myeloid 3Tumor-Agnostic 1Sarcoma 1Plasma cell 1Genitourinary 1Gastrointestinal 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Pancreatic Neoplasms 1Adenocarcinoma 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Etanercept × Gastrointestinal × Clear all
NCT00201838 2017-11-30

Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
38 enrolled 10 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡